TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26674334

Group type: EXPERIMENTAL
Intervention: PACAP38 (n = 16)
Number of subjects: 24

Group type: COMPARATOR
Intervention: VIP (n = 15)
Number of subjects: 24
Study: 24464551

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (GS-7977)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: GS-0938
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of Sofosbuvir and GS-0938
Number of subjects: 32
Study: 22187253

Group type: EXPERIMENTAL
Intervention: Lipid-emulsion propofol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Micro-emulsion propofol
Number of subjects: 36
Study: 19558807

Group type: EXPERIMENTAL
Intervention: Conventional dose ACTH therapy (50 IU per day for 2 weeks, then tapered to zero over 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low dose ACTH therapy (0.4 IU/kg per day for 2 weeks, then tapered to zero over 2 weeks; dosage increased to 1 IU/kg per day if no effective response)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional dose ACTH therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low dose ACTH therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (Conventional and Low dose ACTH therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (initial 8 responders)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cryptogenic WS group
Number of subjects: 30
Study: 17188044

Group type: COMPARATOR
Intervention: Untreated control eyes from six AMD studies
Number of subjects: 6
Study: 16802302

Group type: EXPERIMENTAL
Intervention: Chronic temporal lobe epilepsy patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 46
Study: 14750227

Group type: EXPERIMENTAL
Intervention: Use of a pinhole aperture during the recording of pattern reversal visual evoked potentials
Number of subjects: 0
Study: 11339019

Group type: EXPERIMENTAL
Intervention: Hyperthyroid patients (pre-treatment)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hyperthyroid patients (post-treatment)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperthyroid patients (HRV analysis at rest)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperthyroid patients (HRV analysis during deep breathing test)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 50
Study: 8783690

Group type: EXPERIMENTAL
Intervention: 4 mg/kg on days 1‐5 and 10 (total dose, 24 mg/kg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 3 mg/kg on days 1‐5 and 10 (total dose, 18 mg/kg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 3 mg/kg on days 1‐4 and 10 (total dose, 15 mg/kg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 3 mg/kg for 10 days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 12 mg/kg total dose
Number of subjects: 88
Study: 1623343

Group type: EXPERIMENTAL
Intervention: Insertion of the definitive prosthesis 2 weeks following expansion (immediate)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Insertion of the definitive prosthesis 6 months following expansion (delayed)
Number of subjects: 65
Study: 6714287

Group type: EXPERIMENTAL
Intervention: Hydergine special (1 x 4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydergine forte (2 x 2 mg)
Number of subjects: 0
Study: 29953095

Group type: EXPERIMENTAL
Intervention: Transanal total mesorectumectomy (TA-TME)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Laparoscopic total mesorectumectomy (Lap-TME)
Number of subjects: 34
Study: 28361573

Group type: EXPERIMENTAL
Intervention: YYIRT at 17:00 h
Number of subjects: 11

Group type: COMPARATOR
Intervention: YYIRT at 07:00 h
Number of subjects: 11
Study: 25840767

Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl (2 μg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous morphine (0.1 mg/kg)
Number of subjects: 0
Study: 23123043

Group type: EXPERIMENTAL
Intervention: Specific medical food (400 ml daily for one week, high in protein and leucine, enriched with fish oil and specific oligosaccharides)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Iso-caloric/iso-nitrogenous product (Control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Specific medical food (Active group)
Number of subjects: 38
Study: 21385346

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training (IMST)
Number of subjects: 69

Group type: COMPARATOR
Intervention: SHAM treatment
Number of subjects: 69
Study: 18206175

Group type: EXPERIMENTAL
Intervention: Folate treatment (5 mg folic acid per day, 50 mg vitamin B6 per day, 1,000 microg vitamin B12 per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study: 15898379

Group type: EXPERIMENTAL
Intervention: Antibacterial fluoride‐releasing adhesive
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (standard adhesive)
Number of subjects: 40
Study: 12949712

Group type: EXPERIMENTAL
Intervention: Radiofrequency energy delivery to the gastroesophageal junction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 64
Study: 11083735

Group type: EXPERIMENTAL
Intervention: Metoprolol treatment for 12 months
Number of subjects: 41
Study: 8866582

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray ad libitum (n=45)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nicotine nasal spray fixed dosage of 1 mg x h‐1 during the day (n=44)
Number of subjects: 89
Study: 1503915

Group type: EXPERIMENTAL
Intervention: Mitozantrone, 14 mg m‐2 intravenously every 3 weeks (n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Megesterol acetate, 160 mg bd (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mitozantrone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Megesterol acetate
Number of subjects: 60
Study: 6510459

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination with terbutaline (Theophylline)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination with terbutaline (Enprofylline)
Number of subjects: 6
Study: 31699167

Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 290

Group type: COMPARATOR
Intervention: Breastfed infants (non-smoking mothers)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Formula-fed infants (smoking mothers)
Number of subjects: 290
Study: 31422671

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA+DHA) at a dose of 4 g/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA only) at a dose of 4 g/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA+DHA or EPA-only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPA-only (4 g/d) in REDUCE-IT trial
Number of subjects: 0
Study: 28420644

Group type: EXPERIMENTAL
Intervention: Complete abstinence from smoking (n=70)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Intermittent smoking (n=68)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Persistent smoking (n=34)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Comparison of abstainers to persistent smokers
Number of subjects: 172
Study: 27075874

Group type: EXPERIMENTAL
Intervention: Interceptor LN (200 mg/m(2) alpha‐cypermethrin)
Number of subjects: 934

Group type: COMPARATOR
Intervention: Conventional treated nets (CTN) (40 mg/m(2) alpha‐cypermethrin)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Interceptor LN
Number of subjects: 934

Group type: COMPARATOR
Intervention: CTN
Number of subjects: 934
Study: 24773470

Group type: EXPERIMENTAL
Intervention: Rotational technique (n = 90)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard technique (n = 91)
Number of subjects: 181
Study: 22967478

Group type: EXPERIMENTAL
Intervention: Personality stimuli
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Negative stimuli
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Negative physical stimuli
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Positive stimuli
Number of subjects: 15
Study: 18849014

Group type: EXPERIMENTAL
Intervention: Baseline hyperplastic polyps
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Proximal hyperplastic polyps
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Distal hyperplastic polyps
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Subjects without hyperplastic polyps
Number of subjects: 1637
Study: 17519148

Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptive vaginal ring (CVR) delivering Nestorone (NES) and ethinyl estradiol (EE) (150/15 microg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combined oral contraceptive (OC) providing levonorgestrel (LNG) and ethinyl estradiol (EE) (150/30 microg per tablet)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of CVR and OC
Number of subjects: 45
Study: 15550579

Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1035
Study: 11258118

Group type: EXPERIMENTAL
Intervention: General internal reference prices
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Seller context
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Specific internal reference prices
Number of subjects: 144
Study: 9034228

Group type: EXPERIMENTAL
Intervention: NOCTE (1 x 30 mg at 21.00 h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BID (15 mg at 21.00 h and 15 mg at 09.00 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: NOCTE and BID
Number of subjects: 20
Study: 8379508

Group type: EXPERIMENTAL
Intervention: 18 mg beta-carotene, 900 mg vitamin C, and 200 mg alpha-tocopherol for 6 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no vitamin supplements)
Number of subjects: 22
Study: 3092836

Group type: EXPERIMENTAL
Intervention: CS-514 (20 mg twice a day for 7 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (twice a day for 7 days)
Number of subjects: 10
Study: 30151705

Group type: EXPERIMENTAL
Intervention: Mechanical debridement, 0.12% chlorhexidine mouthwash, and Lactobacillus reuteri (probiotic agent)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mechanical debridement and 0.12% chlorhexidine mouthwash (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus reuteri)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control for probiotics)
Number of subjects: 50
Study: 28848182

Group type: EXPERIMENTAL
Intervention: G‐CSF given during all 6 chemotherapy cycles
Number of subjects: 167

Group type: COMPARATOR
Intervention: G‐CSF limited to the first 2 chemotherapy cycles
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: All patients (both groups)
Number of subjects: 167
Study: 25456153

Group type: EXPERIMENTAL
Intervention: Lutein-enriched egg yolk with skimmed milk (n = 25)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Lutein-enriched egg yolk with buttermilk (n = 23)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Traditionally prepared buttermilk without egg yolk (n = 21)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Traditionally prepared buttermilk with egg yolk (n = 23)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Lutein-enriched egg yolk groups (both buttermilk and skimmed milk)
Number of subjects: 92
Study: 24811959

Group type: EXPERIMENTAL
Intervention: Soft contact lens (SCL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable lens (RGPL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Spectacle wear
Number of subjects: 24
Study: 22654449

Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg) with 2 L PEG solution
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo with 2 L PEG solution
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg) with 2 L PEG solution (after excluding severe constipation)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo with 2 L PEG solution (after excluding severe constipation)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg) with 2 L PEG solution (among previous colonoscopy experience subgroup)
Number of subjects: 250
Study: 19397795

Group type: EXPERIMENTAL
Intervention: Self-monitoring of Blood Glucose (SMBG)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Self-monitoring of Urine Glucose (SMUG)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study: 17301734

Group type: EXPERIMENTAL
Intervention: Tadalafil (10 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15103233

Group type: EXPERIMENTAL
Intervention: Oxytocin given after placenta delivery
Number of subjects: 51
Study: 11311761

Group type: EXPERIMENTAL
Intervention: Oral acyclovir from 36 weeks of gestation to term (group 1)
Number of subjects: 489

Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 489

Group type: COMPARATOR
Intervention: No prophylaxis with a history of genital herpes but no active episodes (group 3)
Number of subjects: 489
Study: 10072236

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7543272

Group type: EXPERIMENTAL
Intervention: Focal irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemibody irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous injection of strontium (89)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single large treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended courses of treatment
Number of subjects: 0
Study: 2250488

Group type: EXPERIMENTAL
Intervention: Medical record audit with feedback
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Computerized cancer screening reminders
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 62
Study: 7363739

Group type: EXPERIMENTAL
Intervention: Early intervention program for high-risk infants
Number of subjects: 60

Group type: COMPARATOR
Intervention: General population infants (control group)
Number of subjects: 60
Study: 31829654

Group type: EXPERIMENTAL
Intervention: Freshmen success intervention (9th grade leadership team, curriculum, peer navigators)
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: Freshmen success intervention
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Control (business as usual)
Number of subjects: 1588
Study: 30852235

Group type: EXPERIMENTAL
Intervention: Heart failure patients (HFpEF)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Heart failure patients (HFpEF) with relevant baseline characteristics included
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 108
Study: 28017311

Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 754
Study: 26026649

Group type: EXPERIMENTAL
Intervention: Intervention group with higher ratings of the helpfulness of the PCPs' involvement
Number of subjects: 347

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 347
Study: 23246476

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 557

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study: 21693215

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally twice daily from day 0 to 7 postoperatively
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 74
Study: 19487934

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17270674

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 716

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 716
Study: 12603367

Group type: EXPERIMENTAL
Intervention: Chronic tension-type headache patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study: 10976543

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8974126

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented total parenteral nutrition (TPN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control TPN
Number of subjects: 0
Study: 1451930

Group type: EXPERIMENTAL
Intervention: sultamicillin 750 mg/day (n = 9)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: sultamicillin 1500 mg/day (n = 46)
Number of subjects: 110

Group type: COMPARATOR
Intervention: cefuroxime axetil 500 mg/day (n = 51)
Number of subjects: 110

Group type: COMPARATOR
Intervention: cefuroxime axetil 1000 mg/day (n = 4)
Number of subjects: 110
Study: 6089581

Group type: EXPERIMENTAL
Intervention: Beta‐adrenoceptor blocker propranolol (160 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3784283

Group type: EXPERIMENTAL
Intervention: Head-out water immersion in Group 1 (N = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Head-out water immersion in Group 2 (N = 8)
Number of subjects: 15
Study: 29906310

Group type: EXPERIMENTAL
Intervention: Every-8-hour vancomycin dosing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Every-8-hour cefepime dosing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Every-12-hour vancomycin dosing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Every-12-hour cefepime dosing
Number of subjects: 20
Study: 26776557

Group type: EXPERIMENTAL
Intervention: Low PIIINP levels
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Baseline ejection fraction
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: PIIINP levels
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels
Number of subjects: 74
Study: 24837754

Group type: COMPARATOR
Intervention: Control group (Web-based smoking cessation intervention)
Number of subjects: 570
Study: 22425637

Group type: EXPERIMENTAL
Intervention: Distal rectus femoris transfer (DRFT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: NON‐DRFT
Number of subjects: 32
Study: 19635945

Group type: EXPERIMENTAL
Intervention: Audiovisual (AV) modality
Number of subjects: 60

Group type: COMPARATOR
Intervention: Audio-only (A-only) modality
Number of subjects: 60
Study: 18428198

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel plus high-dose calcitriol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Weekly docetaxel
Number of subjects: 160
Study: 16147846

Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine penicillin G suspension (Bicillin L‐A), 2.4 million units
Number of subjects: 53

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 53
Study: 14668176

Group type: EXPERIMENTAL
Intervention: Single-task and dual-task complexity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior wakefulness (< 40 h)
Number of subjects: 0
Study: 10883741

Group type: EXPERIMENTAL
Intervention: Active treatment groups
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo groups
Number of subjects: 33
Study: 8836335

Group type: EXPERIMENTAL
Intervention: Complete Program (CP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Reduced Program (RP)
Number of subjects: 65
Study: 1308263

Group type: EXPERIMENTAL
Intervention: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in young females
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in older females
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in both age groups
Number of subjects: 10
Study: 6730871

Group type: EXPERIMENTAL
Intervention: General anesthesia (fentanyl + O2/N2O + postoperative pain relief with systemic opiates)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: General anesthesia + epidural analgesia (local anaesthetics + morphine) continued for 72 h
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-operative control group
Number of subjects: 32
Study: 31319319

Group type: EXPERIMENTAL
Intervention: UN Sustainable Development Goals (SDGs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systems approach to health and social justice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-based approach for communication and engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions delivering health co-benefits
Number of subjects: 0
Study: 30400959

Group type: EXPERIMENTAL
Intervention: Community-based distribution of OraQuick HIV Self Tests by trained lay distributors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard HIV testing (SOC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based distribution of OraQuick HIV Self Tests
Number of subjects: 0
Study: 27313268

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam 2000 mg/500 mg every 8 hours
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Doripenem 500 mg every 8 hours
Number of subjects: 1033
Study: 24320690

Group type: EXPERIMENTAL
Intervention: Aerobic interval training for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study: 22494399

Group type: EXPERIMENTAL
Intervention: Exercise group (60-min bout of cycle ergometry at 90% ventilatory threshold)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (rested for 60 min)
Number of subjects: 30
Study: 20566487

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 152
Study: 18398650

Group type: EXPERIMENTAL
Intervention: Heavyweight double-filament polypropylene mesh (Prolene, 10 x 15 cm, group A, n = 60)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Multifilament heavyweight polypropylene mesh (Serapren, 10 x 15 cm, group B, n = 60)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Composite mesh (polyglactin and polypropylene, Vypro II, 10 x 15 cm, group C, n = 60)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Overall (all groups)
Number of subjects: 180